Shield Therapeutics (STX) Hits New 52-Week High at $119.50

Shares of Shield Therapeutics PLC (LON:STX) hit a new 52-week high on Wednesday . The stock traded as high as GBX 119.50 ($1.56) and last traded at GBX 115 ($1.50), with a volume of 381841 shares changing hands. The stock had previously closed at GBX 114.50 ($1.50).

Several brokerages recently weighed in on STX. FinnCap began coverage on Shield Therapeutics in a research note on Tuesday, May 14th. They set a “corporate” rating and a GBX 200 ($2.61) target price for the company. Peel Hunt reaffirmed a “buy” rating on shares of Shield Therapeutics in a research report on Thursday, May 2nd. Finally, Liberum Capital reaffirmed a “buy” rating on shares of Shield Therapeutics in a research report on Wednesday, April 3rd.

The stock has a market cap of $128.85 million and a PE ratio of -74.11.

In other Shield Therapeutics news, insider James M. Karis purchased 4,000 shares of the stock in a transaction on Tuesday, April 16th. The shares were purchased at an average price of GBX 81 ($1.06) per share, with a total value of £3,240 ($4,233.63). Also, insider Mark Sampson purchased 22,042 shares of the stock in a transaction on Thursday, April 25th. The shares were acquired at an average cost of GBX 91 ($1.19) per share, for a total transaction of £20,058.22 ($26,209.62).

ILLEGAL ACTIVITY NOTICE: “Shield Therapeutics (STX) Hits New 52-Week High at $119.50” was reported by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/05/24/shield-therapeutics-stx-hits-new-52-week-high-at-119-50.html.

Shield Therapeutics Company Profile (LON:STX)

Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease.

Recommended Story: Overbought

Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.